226 related articles for article (PubMed ID: 31609097)
1. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
Epps QJ; Epps KL; Young DC; Zobell JT
Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
[TBL] [Abstract][Full Text] [Related]
2. State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary.
Epps QJ; Epps KL; Young DC; Zobell JT
Pediatr Pulmonol; 2021 Jul; 56(7):1825-1837. PubMed ID: 33656280
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
4. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
Zobell JT; Epps KL; Young DC; Montague M; Olson J; Ampofo K; Chin MJ; Marshall BC; Dasenbrook E
Pediatr Pulmonol; 2015 Jun; 50(6):552-9. PubMed ID: 25559432
[TBL] [Abstract][Full Text] [Related]
5.
Guzek A; Rybicki Z; Tomaszewski D
Indian J Med Microbiol; 2018; 36(1):119-120. PubMed ID: 29735840
[TBL] [Abstract][Full Text] [Related]
6. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
[TBL] [Abstract][Full Text] [Related]
7. What Is the Evidence for Co-trimoxazole, Clindamycin, Doxycycline, and Minocycline in the Treatment of Methicillin-Resistant
Hong J; Ensom MHH; Lau TTY
Ann Pharmacother; 2019 Nov; 53(11):1153-1161. PubMed ID: 31177803
[No Abstract] [Full Text] [Related]
8. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis.
Champion EA; Miller MB; Popowitch EB; Hobbs MM; Saiman L; Muhlebach MS;
Pediatr Pulmonol; 2014 Mar; 49(3):230-7. PubMed ID: 23765686
[TBL] [Abstract][Full Text] [Related]
9. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial.
Jennings MT; Boyle MP; Weaver D; Callahan KA; Dasenbrook EC
Trials; 2014 Jun; 15():223. PubMed ID: 24925006
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.
Fusco NM; Meaney CJ; Frederick CA; Prescott WA
Ann Pharmacother; 2020 Mar; 54(3):197-204. PubMed ID: 31658825
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
[TBL] [Abstract][Full Text] [Related]
12. Treatment of infections due to resistant Staphylococcus aureus.
Anstead GM; Cadena J; Javeri H
Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.
Branstetter J; Searcy H; Benner K; Yarbrough A; Crowder C; Troxler B
Pediatr Pulmonol; 2020 Dec; 55(12):3337-3342. PubMed ID: 32803907
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance profile of methicillin-resistant
Wu X; Wang C; He L; Xu H; Jing C; Chen Y; Lin A; Deng J; Cao Q; Deng H; Cai H; Chen Y; Yang J; Zhang T; Huang Y; Hao J; Yu H
Front Cell Infect Microbiol; 2023; 13():1102779. PubMed ID: 36743309
[TBL] [Abstract][Full Text] [Related]
15. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan.
Naimi HM; Rasekh H; Noori AZ; Bahaduri MA
BMC Infect Dis; 2017 Nov; 17(1):737. PubMed ID: 29187146
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients.
Belarski E; Pettit R
Pediatr Pulmonol; 2020 Mar; 55(3):654-659. PubMed ID: 31899860
[TBL] [Abstract][Full Text] [Related]
17. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
[TBL] [Abstract][Full Text] [Related]
18. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
Loffler CA; Macdougall C
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.
Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD
Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597
[TBL] [Abstract][Full Text] [Related]
20. [Genetic characterization and antimicrobial susceptibility analysis of methicillin-resistant Staphylococcus aureus isolated from ready-to-eat food and pig-related sources in China].
Wang W; Guo Y; Pei X; Hu Y; Bai L; Sun A; Liu J; Fu P; Li F
Wei Sheng Yan Jiu; 2013 Nov; 42(6):925-31. PubMed ID: 24459903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
